DFU Research & News

This review looked at ways to reduce pain when changing dressings on chronic wounds, including diabetic foot ulcers. Pain during dressing changes is a big problem for patients and can cause stress and fear. The researchers reviewed 29 studies, including tests of treatments, surveys, and interviews with patients and health workers. They found that pain varies greatly and depends on the wound type and healing stage. Some non-adhesive dressings and certain sprays or gels helped reduce pain, but results were mixed and not all methods worked for everyone. The study also showed that how doctors and nurses talk with patients and prepare them before changing dressings can make a difference. This is important because better pain control can help wounds heal and improve quality of life. However, because the studies were very different, it's hard to give one clear recommendation, and more research is needed.

• Pain during dressing changes is common for chronic wounds like diabetic foot ulcers, causing distress and fear.
• This review of 29 studies found that pain varies by wound type and healing stage, and no single method always works.

This case report describes a patient with type 2 diabetes who developed sudden blockage of blood flow to the leg (acute limb ischemia) and a rapidly worsening diabetic foot ulcer with gangrene. The underlying cause was later found to be a rare pancreatic tumor that made the blood abnormally prone to clotting. Doctors used a step-by-step approach to save the limb, including surgery to remove dead tissue and infected bone, skin flap reconstruction, antibiotics, blood thinners, and strict blood sugar control. The wound healed and the patient regained function, but the pancreatic tumor had spread to the liver and required additional treatment. This case highlights that in some diabetic patients with foot gangrene, hidden cancers may be a trigger for blood clots, and a team of specialists is essential for successful treatment. However, as a single case report, its findings may not apply to all patients with diabetic foot ulcers.

• A diabetic patient with foot gangrene had a hidden pancreatic tumor causing blood clots, leading to blocked leg arteries.
• A combination of surgery, antibiotics, blood thinners, and glucose control successfully saved the limb.

Las heridas crónicas como las úlceras del pie diabético son difíciles de curar y costosas de tratar. Un nuevo tipo de apósito, TLC-NOSF, funciona cambiando el entorno de la herida para ayudar a que cicatrice más rápido. En este estudio, los investigadores siguieron a 250 pacientes con heridas crónicas, incluidas úlceras del pie diabético, en Francia. Encontraron que el 78% de las heridas cicatrizaron dentro de las 12 semanas de usar el apósito. El apósito también redujo el dolor y mejoró la calidad de vida. Esto es importante porque ofrece una nueva opción para pacientes que no han cicatrizado con el cuidado estándar. Sin embargo, el estudio no incluyó un grupo de comparación, por lo que se necesita más investigación para confirmar estos resultados.

• Las heridas crónicas como las úlceras del pie diabético son comunes y difíciles de tratar.
• Los apósitos TLC-NOSF ayudan equilibrando las enzimas en la herida que retardan la cicatrización.

This study looked at whether a specific wound dressing—native collagen matrix with PHMB antimicrobial—helps prevent leg amputations in people with diabetic foot ulcers. The researchers analyzed Medicare data from 2015 to 2023, comparing over 10,000 patients who used this dressing with matched patients who did not. They found that patients using the dressing had lower amputation rates within six months, even though they initially had more severe ulcers. Specifically, the amputation rate was 2.7% in the dressing group versus 4.3% in the comparison group, a significant reduction. This suggests that using this advanced dressing may help preserve limbs in high-risk patients. However, the study was observational, so it cannot prove cause and effect, and it only looked at Medicare beneficiaries in the US, so results may not apply globally.

• A new study found that a collagen matrix with antimicrobial reduced six-month amputation rates in diabetic foot ulcer patients from 4.3% to 2.7%.
• The study included over 10,000 matched Medicare beneficiaries, making it one of the largest real-world analyses on this dressing.

A 58-year-old man with diabetes, end-stage kidney disease, and severe peripheral artery disease had a chronic foot ulcer that would not heal despite a year of standard care. Doctors in Palestine tried an injectable collagen-based regenerative therapy, which is a substance that helps the body rebuild tissue. Within three months, the wound completely closed, and the leg was saved from amputation. Later, a burn caused the wound to reopen, but after revascularization surgery to improve blood flow, the healing held. This case suggests that collagen-based therapy may offer a new option for hard-to-heal diabetic foot ulcers, especially when blood flow is poor. However, because this is a single case, more research is needed to confirm its effectiveness and safety in larger groups.

• A diabetic foot ulcer with poor blood flow healed completely in three months after injectable collagen therapy, saving the patient's leg from amputation.
• The patient had multiple complicating conditions, including kidney failure, yet the therapy still promoted wound closure.

Diabetes can cause wounds, especially on the feet, to heal very slowly, and this is a common and serious problem. The core issue is that high blood sugar leads to persistent inflammation and poor blood flow, which causes scar tissue to build up abnormally, a process called fibrosis. This review article looked at how leech, a traditional Chinese medicine, might help with this problem. The authors reviewed existing research and found that leech has multiple effects: it can reduce inflammation, improve blood circulation, and block key signals that drive fibrosis. Specifically, leech may reduce the buildup of scar tissue by targeting several signaling pathways, but the exact active ingredients and how they work together are still not fully known. The study suggests leech could be a promising addition to diabetic ulcer treatment, but more research is needed. No specific numbers or percentages were provided because this is a review, not an original study. The main limitation is that most evidence is from laboratory or animal studies, and human trials are needed to confirm benefits.

• Leech, a traditional Chinese medicine, may help heal diabetic foot ulcers by reducing inflammation and improving blood flow.
• The review explains that leech can interfere with scar tissue formation by blocking several important signaling pathways.

Diabetic patients with Charcot foot often develop hard-to-heal ulcers on the bottom of the foot due to abnormal pressure and instability. Traditional casts protect the foot but make it difficult to check the wound or change dressings. This study tested a modified cast with a window and an angled ankle position to allow easier wound care. Doctors in Egypt treated 48 diabetic patients with chronic plantar ulcers using this new cast. Complete healing was achieved in 91.7% of the patients, and only a small number developed complications like infection or pressure sores. The findings suggest that this modified cast can be a safe and effective option for resistant ulcers. However, the study was single-center and did not compare with standard casting, so more research is needed to confirm its benefits.

• A modified windowed angled cast helped 91.7% of patients with difficult diabetic foot ulcers heal completely, according to a new study.
• This cast allows doctors to inspect the wound and change dressings without removing the whole cast, which may improve care.

Diabetic foot ulcers are a serious complication of diabetes, affecting about 25% of patients and often leading to amputation. This study looked at how a type of white blood cell, called neutrophils, may contribute to poor healing. Neutrophils can form web-like structures called NETs, which normally trap germs, but too many NETs can cause inflammation that prevents wounds from healing. Researchers analyzed genetic data from 20 patients (9 from one study and 11 from another) using advanced techniques to compare healing and non-healing wounds. They found that non-healing wounds had much higher NET activity, with a 43.1% expansion of a specific neutrophil subtype linked to NETs compared to 15.4% in healing wounds. They also identified a 6-gene signature that could predict healing with 75% accuracy. These findings suggest that targeting NETs could be a new way to treat diabetic foot ulcers, and the gene signature might help doctors identify patients at risk for poor healing. However, the study is still early, and the results need validation in larger, prospective studies.

• Diabetic foot ulcers affect 25% of diabetics and are a leading cause of amputations, making better treatments crucial.
• This study found that NETs, immune cell traps, are overactive in non-healing wounds, causing chronic inflammation.

Diabetic foot ulcers (DFUs) are a serious complication of diabetes, affecting 19-34% of patients and with a five-year mortality rate of 50-70%, often due to poor healing and infections. Current treatments are limited, leading to antibiotic resistance and amputations. This review explores combining natural plant extracts (like curcumin and flavonoids) with conventional drugs in advanced delivery systems such as hydrogels and nanofibers. These plant extracts have antibacterial and anti-inflammatory properties, while drugs help control infection and metabolism, but they work better together. The study analyzed existing research, not new experiments, and found that this combination could improve healing by addressing multiple wound problems at once. However, the authors note that natural extracts can be unstable and vary in quality, which may affect results. This approach is promising but needs more clinical trials to confirm safety and effectiveness in humans.

• Diabetic foot ulcers affect up to 34% of diabetics, with high mortality and amputation risk, so better treatments are urgent.
• Combining plant extracts like curcumin with antibiotics or other drugs in smart bandages may boost healing.

Las úlceras del pie diabético son heridas de difícil cicatrización que ocurren en personas con diabetes, a menudo debido al alto nivel de azúcar en sangre y a la mala circulación sanguínea. Pueden quedar atrapadas en un ciclo de inflamación, exceso de radicales libres de oxígeno, bajo nivel de oxígeno e infección. Los apósitos tradicionales simplemente cubren la herida pero no abordan estos problemas subyacentes. Este estudio, una revisión, analiza los materiales 'inteligentes' que pueden detectar y responder activamente al entorno de la herida. Los investigadores destacan cuatro tipos: materiales sensibles a la glucosa para reducir el azúcar, antioxidantes para eliminar los radicales libres dañinos, materiales generadores de oxígeno para mejorar el suministro de oxígeno y materiales antibacterianos para combatir la infección. Estos materiales inteligentes tienen como objetivo impulsar la cicatrización al abordar los problemas específicos en las heridas diabéticas. Muestran promesa, pero se necesita más investigación para confirmar su efectividad en personas, y aún no están ampliamente disponibles en las clínicas.

• Las úlceras del pie diabético son difíciles de curar debido al alto nivel de azúcar en sangre, la inflamación y la infección. Los materiales inteligentes pueden ayudar al abordar estos problemas directamente.
• Los investigadores revisaron cuatro enfoques innovadores: materiales para el control de la glucosa, antioxidantes, potenciadores de oxígeno y antibacterianos para la cicatrización de heridas.

Las heridas crónicas, como las úlceras del pie diabético, no cicatrizan porque las propias células de reparación del cuerpo se vuelven disfuncionales. Este artículo de investigación de China revisa un nuevo enfoque llamado reprogramación celular, que tiene como objetivo 'reescribir' la identidad de estas células para restaurar su función de curación. Los autores proponen una 'caja de herramientas tecnológicas de cuatro dimensiones' que incluye factores de transcripción, moléculas pequeñas, cambios epigenéticos y metabólicos, y nanomateriales para administrar estos cambios. Se centran en reprogramar tres tipos clave de células: fibroblastos (para reducir la cicatrización y promover la regeneración), queratinocitos (para reconstruir la barrera cutánea) y macrófagos (para pasar de la inflamación a la reparación). Los hallazgos sugieren que estas estrategias podrían potencialmente corregir la causa raíz de las heridas que no cicatrizan, ofreciendo un nuevo camino más allá de los tratamientos tradicionales. Sin embargo, esta es una revisión de enfoques experimentales, no un ensayo clínico, por lo que estas técnicas aún no están disponibles en los hospitales. Para los pacientes, esto destaca una dirección futura emocionante, pero la atención actual aún se basa en métodos probados como el desbridamiento, el control de infecciones y la descarga. Es importante tener en cuenta que se necesitan más investigaciones y pruebas clínicas antes de que estos métodos de reprogramación estén disponibles.

• La reprogramación celular puede ayudar a curar heridas crónicas al corregir las células de reparación defectuosas, no solo tratar los síntomas.
• La estrategia se dirige a fibroblastos, queratinocitos y macrófagos para promover la regeneración en lugar de la cicatrización.

Las úlceras del pie diabético son una complicación grave de la diabetes que puede llevar a la discapacidad o incluso la muerte, y muchos pacientes no responden bien a los tratamientos actuales. Este artículo de revisión examinó una nueva terapia llamada Plasma Frío Atmosférico (CAP), que utiliza gas ionizado para producir especies reactivas de oxígeno y nitrógeno que combaten las bacterias y ayudan a que las heridas cicatricen. Los investigadores revisaron estudios de laboratorio y algunas pruebas en animales, mostrando que el CAP puede matar bacterias, promover el crecimiento celular y reducir la inflamación en las úlceras del pie diabético. Sin embargo, encontraron que hay una falta de ensayos clínicos de alta calidad en humanos, por lo que aún no se ha demostrado que funcione en pacientes reales. El principal beneficio es que el CAP podría ser eficaz sin causar resistencia a los medicamentos, lo cual es un gran problema para los pacientes que necesitan antibióticos a largo plazo. Aún así, se necesita más investigación antes de que pueda recomendarse como tratamiento estándar.

• Las úlceras del pie diabético son difíciles de curar y pueden causar daños graves; se necesitan nuevos tratamientos.
• El Plasma Frío Atmosférico (CAP) produce especies reactivas que matan bacterias y promueven la curación en estudios de laboratorio.

Diabetic foot ulcers are a serious complication of diabetes, affecting up to 34% of diabetic patients and recurring in about 40% within a year. This review focuses on how the gut microbiota—the community of bacteria in the digestive tract—influences the healing of these ulcers. The researchers examined existing studies to understand how gut bacteria affect the immune system and inflammation, which are key to wound healing. They found that an imbalance in gut bacteria may slow healing, while certain strategies to restore balance, such as probiotics, prebiotics, fecal microbiota transplantation, and dietary changes, could reduce inflammation and promote healing. These findings are significant because they suggest that targeting the gut microbiome could be a new way to help heal diabetic foot ulcers. However, this is a review of existing research, not a new clinical trial, and more studies are needed to confirm the effectiveness of these interventions in patients.

• Gut microbiota play a key role in healing diabetic foot ulcers by regulating immune balance and inflammation.
• Probiotics, prebiotics, and fecal transplants may help restore healthy gut bacteria and speed up wound healing.

Diabetic foot ulcers are a serious complication of diabetes that can lead to amputation if not treated effectively. For patients who do not respond to standard care, such as cleaning the wound and using antibiotics, new surgical options are being explored. In this study, researchers tested a combination of two techniques: moving a small piece of bone from the shin to improve blood flow (tibial transverse transport) and using a two-stage procedure to fill bone gaps (Masquelet technique). The study included 46 patients with moderate-to-severe ulcers (Wagner stages 2-4), half of whom received the new combined surgery and half received standard treatment. Results showed that the surgery group had a higher rate of complete wound healing, with 87% of patients achieving full closure compared to 52% in the standard care group. Additionally, the surgery group had a shorter time to healing (around 2.5 months versus 4 months) and a lower rate of ulcer recurrence at 6 months. Importantly, limb salvage was achieved in all surgery patients, whereas two patients in the standard group required amputation. These findings suggest that this combined surgical approach could significantly benefit patients with stubborn diabetic foot ulcers, but more research is needed to confirm the long-term outcomes and the best candidates for this surgery.

• The combined surgery (tibial transverse transport + Masquelet) improved complete wound healing to 87% vs. 52% with standard care.
• Patients who had surgery healed faster: about 2.5 months on average compared to 4 months.

Chronic wounds like diabetic foot ulcers (DFUs) are hard to heal because they stay inflamed due to poor blood flow and signaling problems. This article reviews photobiomodulation (PBM), a non-invasive light therapy that uses specific wavelengths to stimulate cells, helping them produce more energy and reduce inflammation. PBM works by releasing nitric oxide from a key enzyme in mitochondria, allowing cells to resume normal function and ATP production. The review discusses how PBM can promote healing in chronic wounds and radiation-induced fibrosis by upregulating growth factors and boosting fibroblast activity. While PBM shows promise as an adjunct treatment, its use is limited by a lack of standardized protocols, and more studies are needed to determine optimal dosing and long-term benefits. The article highlights the need for further research to establish safety and cost-effectiveness before widespread clinical adoption.

• PBM uses light to stimulate cell energy production, aiding wound healing in chronic conditions like diabetic foot ulcers.
• This review explains that PBM reduces inflammation and promotes fibroblast activity, which are key to healing.

This article explains how photobiomodulation (PBM), a type of light therapy using red and near-infrared light, can help heal hard-to-heal wounds like diabetic foot ulcers. The therapy works by stimulating cells in the wound to function better, reducing inflammation, and improving blood flow. The study describes the specific treatment settings needed for safe and effective use, such as dose and timing. It highlights that a THOR LED device can deliver a therapeutic dose in just 60 seconds. PBM is intended to be used alongside standard wound care, not as a replacement. The article is based on expert knowledge and company-supported information, so more independent research may be needed. For patients, this means a potentially quick, painless addition to their wound care routine, but they should discuss with their doctor.

• PBM is a painless light therapy that may help heal diabetic foot ulcers by reducing inflammation and boosting cell function.
• A single PBM treatment can be done in just 60 seconds, making it convenient for clinical settings.

Chronic wounds, such as diabetic foot ulcers, are hard to heal and can seriously affect quality of life. This study compared two treatments made from blood platelets: one using the patient's own blood (autologous) and one using donated blood (allogeneic). The researchers followed 17 patients with persistent wounds and measured how much the wound size decreased, the quality of new tissue growth, and healing time. They found that both treatments helped wounds heal, but allogeneic platelet-rich fibrin was especially useful for patients who could not use their own blood due to conditions like diabetes. The allogeneic treatment appeared to work as well as the autologous one, making it a promising option for patients who need an alternative. However, the study was small, and more research is needed to confirm these results and understand long-term effects.

• Chronic wounds like diabetic foot ulcers are difficult to treat and affect many people.
• This study compared using a patient's own platelets versus donor platelets for wound healing.

This study looked at how to predict whether diabetic foot ulcers (DFUs) will heal, using data from over 1,000 patients in Tanzania, a setting with limited healthcare resources. Researchers tracked patients for an average of about 5.5 months and found that most ulcers (96%) healed, while 36 did not. They used a scoring system called SINBAD, which grades ulcers based on factors like depth, size, and blood flow. Higher SINBAD scores were linked to a higher risk of the ulcer not healing and longer healing times. Specifically, ulcers with SINBAD scores of 4, 5, or 6 had 50%, 60%, and 70% higher risks of not healing, and took 2.2, 2.8, and 3.3 times longer to heal, compared to a score of 3. Deeper ulcers and a history of ulcers also increased the risk of non-healing by 68% and 47%, respectively. Delaying treatment by one day increased the risk of non-healing by 0.5%, and larger ulcers (>1 cm²) took 2.4 times longer to heal. This research highlights the importance of early and comprehensive assessment in predicting outcomes and managing DFUs, even in resource-limited settings, which can guide doctors in prioritizing care.

• Higher SINBAD scores (4, 5, 6) mean up to 70% higher risk of ulcer not healing and healing time up to 3.3 times longer.
• Deeper ulcers and having had a previous ulcer increase the risk of non-healing by 68% and 47%, respectively.

Diabetic foot ulcers are a serious and common complication of diabetes that can lead to infection and even amputation if not treated properly. Current treatments focus on wound care, infection control, and offloading, but there is growing interest in whether vitamin C, an antioxidant, can speed up healing. This study protocol describes a randomized, placebo-controlled double-blind trial that will test the efficacy of vitamin C supplementation in aiding foot ulcer healing in people with diabetes. The trial will recruit 200 participants and follow them for 24 weeks, measuring the reduction in ulcer area and time to complete healing. The researchers expect that vitamin C will significantly reduce ulcer size and improve healing rates, with fewer adverse events compared to placebo. If proven effective, this could offer a simple, low-cost addition to standard DFU care. However, this is a protocol paper, so the results are not yet available, and the true benefits remain uncertain until the trial is completed and published.

• Diabetic foot ulcers are serious and can lead to amputation; effective treatments are urgently needed.
• This is a study protocol for a randomized, double-blind, placebo-controlled trial testing vitamin C in 200 patients.